Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nektar Therapeutics (NQ: NKTR )

1.170 -0.010 (-0.85%)
Streaming Delayed Price Updated: 9:44 AM EDT, Sep 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,478
Open 1.160
Bid (Size) 1.160 (28)
Ask (Size) 1.170 (3)
Prev. Close 1.180
Today's Range 1.155 - 1.170
52wk Range 0.4126 - 1.928
Shares Outstanding 183,801,441
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NKTR Stock Earnings: Nektar Therapeutics Misses EPS, Beats Revenue for Q2 2024
NKTR stock results show that Nektar Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
NKTR Stock Earnings: Nektar Therapeutics Meets EPS, Beats Revenue for Q1 2024
NKTR stock results show that Nektar Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+96.70%
+96.70%
1 Month
+5.41%
+5.41%
3 Month
-2.90%
-2.90%
6 Month
+40.68%
+40.68%
1 Year
+80.00%
+80.00%

More News

Read More
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Sweet Nektar?
Via Talk Markets
Nektar Therapeutics Earnings Preview
Via Benzinga
Recap: Nektar Therapeutics Q3 Earnings
Via Benzinga
A Preview Of Nektar Therapeutics's Earnings
Via Benzinga
Expert Ratings for Nektar Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Biotech's Lawsuit With Eli Lilly Might Catalyze Stock
Via Talk Markets
Topics Lawsuit
Exposures Financial Legal
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Nektar Therapeutics: Q1 Earnings Insights
Via Benzinga
Earnings Scheduled For March 4, 2024
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
The One-Minute Market Report - Saturday, Aug. 12
Via Talk Markets
Topics ETFs
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Is Nektar Therapeutics Stock Surging Today?
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
Via Benzinga
Tempur Sealy International To Rally Around 32%? Here Are 10 Other Analyst Forecasts For Wednesday
Via Benzinga
Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions
Via Benzinga
7 Sorry Pharma Stocks to Sell in April Before It’s Too Late
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.